<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05058755</url>
  </required_header>
  <id_info>
    <org_study_id>XHLSG-NK-1903</org_study_id>
    <nct_id>NCT05058755</nct_id>
  </id_info>
  <brief_title>Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma</brief_title>
  <official_title>Efficacy and Safety of Tislelizumab Combined Treatment in Refractory Natural Killer/T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Natural killer/T-cell lymphoma (NKTCL) patients with relapsed/refractory disease had very&#xD;
      poor outcome. Anti-PD-1 antibody showed promising results in response, but but the complete&#xD;
      remission rate of was low. Some anti-PD-1 antibody based regimen showed higher and deeper&#xD;
      response in NKTCL patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 20-30% of early-stage patients and 40-60% of late-stage NKTCL patients will experience&#xD;
      disease relapse and refractory disease, and the median survival time of relapsed patients is&#xD;
      about 6 months. PD-1 antibody is an effective drug for the treatment of patients with&#xD;
      relapsed/refractory NKTCL, but the response rate and complete remission rate of monotherapy&#xD;
      are low. How to improve the prognosis of patients is an important way to try combination&#xD;
      therapy. In this study, we aim to explore the effectiveness and safety of a novel anti-PD-1&#xD;
      antibody, tislelizumab, in combination with different drugs (tislelizumab plus azacytidine&#xD;
      and lenalidomide, or tislelizumab plus etoposide and pegaspargase) to treat refractory NK/T.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Week 12 +/-7 days</time_frame>
    <description>The overall response rate will be assessed on Week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>Week 12 +/-7 days</time_frame>
    <description>The complete response rate will be assessed on Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>1-year</time_frame>
    <description>Progression free survival is the time from entry onto the treatment until lymphoma progression or death of any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1-year</time_frame>
    <description>Overall survival is defined as the time from entry onto the treatment until death of any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-Related Adverse Events as Assessed by CTCAE v5.0</measure>
    <time_frame>Treatment-Related Adverse Events will be assessed and graded by NCI CTCAE v5.0.</time_frame>
    <description>From day 1 of each course of chemotherapy to the 3 months after the last dose of therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type</condition>
  <arm_group>
    <arm_group_label>TALE regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tislelizumab plus azacytidine and lenalidomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TEPA regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tislelizumab plus etoposide and pegaspargase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tislelizumab, azacytidine, lenalidomide</intervention_name>
    <description>tislelizumab, 200mg, iv, day 1, every 21 days.&#xD;
azacytidine, 75mg/m2, ih, days 1-7, every 21 days.&#xD;
lenalidomide, 25mg, po, days 1-14, every 21 days.</description>
    <arm_group_label>TALE regimen</arm_group_label>
    <other_name>Tileilizhu Dankang</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tislelizumab, etoposide, pegaspargase</intervention_name>
    <description>tislelizumab, 200mg, iv, day 1, every 21 days.&#xD;
etoposide, 100mg, iv, days 1-3, every 21 days.&#xD;
pegaspargase, 2000U/m2, day 1, every 21 days</description>
    <arm_group_label>TEPA regimen</arm_group_label>
    <other_name>Tileilizhu Dankang</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with biopsy histopathology, immunohistochemistry and EBER test meet ing the&#xD;
             WHO 2016 diagnostic criteria for NK/T cell lymphoma.&#xD;
&#xD;
          2. With progressive disease after asparaginase-based combined chemotherapy&#xD;
&#xD;
          3. Have experienced multiple courses of PD-1/PD-L1 treatment with non-responsive or&#xD;
             progressive disease.&#xD;
&#xD;
          4. PET/CT or CT/MRI with at least one measurable lesion or objectively evaluable lesion.&#xD;
&#xD;
          5. General ECOG score 0-3 points.&#xD;
&#xD;
          6. The laboratory examination within 1 week before enrollment meets the following&#xD;
             conditions:&#xD;
&#xD;
             Blood routine: Hb&gt;80g/L, PLT&gt;50×109/L. Liver function: ALT, AST, TBIL ≤ 2 times the&#xD;
             upper limit of normal. Renal function: Cr is normal. Blood coagulation test: plasma&#xD;
             fibrinogen ≥1.0g/L. Heart function: LVEF≥50%, ECG did not indicate any acute&#xD;
             myocardial infarction, arrhythmia, or atrioventricular block of degree I or more.&#xD;
&#xD;
          7. Signed informed consent form.&#xD;
&#xD;
          8. Voluntarily comply with research protocols, follow-up plans, laboratory and auxiliary&#xD;
             examinations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a history of pancreatitis (only patients who are planning to undergo PD1&#xD;
             combined with pegaspargase are excluded).&#xD;
&#xD;
          2. Severe infections require ICU treatment.&#xD;
&#xD;
          3. Combined HCV or HIV infection. Patients with HBV infection who receive antiviral&#xD;
             treatment at the same time will not be excluded.&#xD;
&#xD;
          4. There are serious complications such as fulminant DIC.&#xD;
&#xD;
          5. Impairment of important organ functions: such as respiratory failure, chronic&#xD;
             congestive heart failure with NYHA grade ≥2, decompensated liver or kidney&#xD;
             insufficiency, hypertension and diabetes that cannot be controlled despite active&#xD;
             treatment, nearly 6 years old There were cardio-cerebrovascular thrombotic or&#xD;
             hemorrhagic events within months.&#xD;
&#xD;
          6. Pregnant and lactating women.&#xD;
&#xD;
          7. Have a history of autoimmune diseases, have disease activity in the past 6 months, and&#xD;
             are still receiving oral immunosuppressive therapy within the past three months, and&#xD;
             the daily dose of oral prednisone is greater than 10 mg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rong Tao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rong Tao, MD</last_name>
    <phone>0086-21-25077604</phone>
    <email>hkutao@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chuanxu Liu, MD</last_name>
    <phone>0086-21-25077605</phone>
    <email>linchuanxu@xinhuamed.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xinhua Hospital,Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rong Tao, MD</last_name>
      <phone>0086-21-25077604</phone>
      <email>hkutao@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Chuanxu Liu, MD</last_name>
      <phone>0086-21-25077605</phone>
      <email>liuchuanxu@xinhuamed.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Chuanxu Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rong Tao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 17, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Rong Tao</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

